DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its ...
Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.
DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...
Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results